$14.25
0.28% yesterday
Nasdaq, Dec 24, 07:05 pm CET
ISIN
US03152W1099
Symbol
FOLD

Amicus Therapeutics, Inc. Stock price

$14.25
+4.36 44.08% 1M
+8.54 149.56% 6M
+4.83 51.27% YTD
+4.46 45.56% 1Y
+2.58 22.11% 3Y
-9.98 41.19% 5Y
+4.85 51.60% 10Y
-0.18 1.25% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.04 0.28%
ISIN
US03152W1099
Symbol
FOLD
Industry

Key metrics

Basic
Market capitalization
$4.4b
Enterprise Value
$4.5b
Net debt
$128.1m
Cash
$263.8m
Shares outstanding
308.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.4 | 6.9
EV/Sales
7.6 | 7.1
EV/FCF
468.1
P/B
19.1
Financial Health
Equity Ratio
24.7%
Return on Equity
-28.9%
ROCE
5.2%
ROIC
-
Debt/Equity
1.7
Financials (TTM | estimate)
Revenue
$598.7m | $641.8m
EBITDA
$42.1m | $46.7m
EBIT
$34.5m | $49.2m
Net Income
$-14.1m | $-5.8m
Free Cash Flow
$9.7m
Growth (TTM | estimate)
Revenue
21.3% | 21.5%
EBITDA
82.4% | 9.6%
EBIT
139.7% | 44.5%
Net Income
86.6% | 89.6%
Free Cash Flow
130.8%
Margin (TTM | estimate)
Gross
89.8%
EBITDA
7.0% | 7.3%
EBIT
5.8%
Net
-2.4% | -0.9%
Free Cash Flow
1.6%
More
EPS
$-0.1
FCF per Share
$0.0
Short interest
6.3%
Employees
499
Rev per Employee
$1.1m
Show more

Is Amicus Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Amicus Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Amicus Therapeutics, Inc. forecast:

15x Buy
88%
2x Hold
12%

Analyst Opinions

17 Analysts have issued a Amicus Therapeutics, Inc. forecast:

Buy
88%
Hold
12%

Financial data from Amicus Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
599 599
21% 21%
100%
- Direct Costs 61 61
24% 24%
10%
537 537
21% 21%
90%
- Selling and Administrative Expenses 353 353
15% 15%
59%
- Research and Development Expense 142 142
25% 25%
24%
42 42
82% 82%
7%
- Depreciation and Amortization 7.60 7.60
13% 13%
1%
EBIT (Operating Income) EBIT 35 35
140% 140%
6%
Net Profit -14 -14
87% 87%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Amicus Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amicus Therapeutics, Inc. Stock News

Positive
Seeking Alpha
3 days ago
BioMarin, along with Sanofi, is a leader in the rare disease therapeutics market. It has an extensive portfolio of enzyme replacement therapies, including Palynziq, Vimizim, and Brineura. For example, sales of Brineura, approved for CLN2 disease, reached $48 million in Q3, up 29.7% year-on-year.
Neutral
PRNewsWire
6 days ago
MILWAUKEE , Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.
Positive
Barrons
6 days ago
It's the second acquisition for BioMarin in 2025, as the company seeks to diversify its product portfolio after the commercial failure of a hemophilia A gene therapy.
More Amicus Therapeutics, Inc. News

Company Profile

Amicus Therapeutics, Inc. is a biotechnology company. It engages in the discovery, development, and commercialization of novel treatments for patients living with rare and orphan diseases. Its product includes migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.

Head office United States
CEO Bradley Campbell
Employees 499
Founded 2002
Website www.amicusrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today